Eli Lilly & Co. (LLY) Declares $0.51 Quarterly Dividend; 2.7% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Lilly Declares Second-Quarter 2016 Dividend
May 2, 2016 2:28 PM EDTINDIANAPOLIS, May 2, 2016 /PRNewswire/ --Â The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2016 of $0.51 per share on outstanding common stock.
The dividend is payable June 10, 2016, to shareholders of... More
Lilly Declares Second-Quarter 2016 Dividend
May 2, 2016 2:28 PM EDTINDIANAPOLIS, May 2, 2016 /PRNewswire/ --Â The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2016 of $0.51 per share on outstanding common stock.
The dividend is payable June 10, 2016, to shareholders of... More
Lilly's Taltz® (ixekizumab) Now Available in the U.S. for the Treatment of Moderate-to-Severe Plaque Psoriasis
May 2, 2016 2:00 PM EDTINDIANAPOLIS, May 2, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Taltz® (ixekizumab) injection 80 mg/mL for the treatment of moderate-to-severe plaque psoriasis is now available by prescription order through a contracted network of specialty pharmacies in the United States. Lilly is also offering patient support programs to help ensure eligible patients have access to Taltz and available resources.Â
Taltz was approved by the U.S. FDA in March 2016 for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systematic therapy or phototherapy.... More
Largest Independent U.S. Psoriasis Registry to Track Safety of New Biologic Treatment
May 2, 2016 12:00 PM EDTPORTLAND, Ore., May 2, 2016 /PRNewswire-USNewswire/ -- The Corrona Psoriasis Registry announced it will track the drug safety reporting for ixekizumab, a new biologic medication by Eli Lilly and Company (NYSE: LLY) that was recently approved for the treatment of moderate-to-severe plaque psoriasis. The registry is a joint collaboration between the National Psoriasis Foundation (NPF) and Corrona, LLC, the leading sponsor of registries in autoimmune disease.
The registry will enroll at least 4,000 people with psoriasis on ixekizumab and follow their treatment for at least eight years. Over 1,200 people on various... More
